( WALTHAM Mass.--(BUSINESS WIRE)--May 7...)OXiGENE Announces a Poster Presentation Highlighting Results from,its Study of ZYBRETSTAT CA4P in Myopic Macular Degeneration (Study,MMD-213) at the 47th Annual Meeting of the Association of Research,in Vision and Ophthalmology,Health

WALTHAM, Mass.--(BUSINESS WIRE)--May 7, 2007 - OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a clinical-stage biotechnology company developing novel therapeutics to treat cancer and eye diseases, announced today that the results of its Phase II combretastatin A4 phosphate (CA4P) clinical trial in myopic macular degeneration (MMD) was presented at the 47th Annual Meeting of the Association of Research in Vision and Ophthalmology (ARVO) in Fort Lauderdale, FL. The abstract may be viewed at www.arvo.org.

The following are the poster session details: -0-

Poster No.:   1457/B534

Abstract      Phase II Clinical Trial of Intravenous Combretastatin A4

 Title:        Phosphate in Patients With Subfoveal Choroidal

               Neovascular Membranes (CNV) in Pathologic Myopia

Presentation  Monday, May 07, 2007, 8:30 AM -10:15 AM

 Time:

The poster provided additional details from the ZYBRESTAT(TM) CA4P Phase II clinical trial (MMD-213) in Myopic Macular Degeneration, top-line results from which the Company previously announced on February 15, 2007. Based on the positive results from this study, in which 100% of patients met the primary endpoint of maintenance of visual acuity, the Company has held a pre-IND meeting with the FDA regarding topical ophthalmic formulations (eye drops and ocular mini-tabs), is proceeding with development of a topical formulation of ZYBRESTAT(TM), and anticipates filing and IND and initiating clinical studies with the formulation in early 2008.

About the Study (MMD-213):

MMD-213 was a Phase II, double-masked (physician and subject), dose-ranging, multi-center study designed to evaluate the safety and efficacy of intravenous CA4P for treating subfoveal choroidal neovascularization in subjects with pathologic myopia. Subjects were assigned to receive CA4P at doses of 27, 36 or 45 mg/m(2). A total of 23 subjects, 7-8 per arm, were enrolled. All subjects receive
'"/>

Page: 1 2 3
Related medicine technology :

1. OXiGENE Abstracts Published in ASCO Program
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference